WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2023 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2023.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
A07EA06budesonide2mgSL
A10BG04lobeglitazone0.5mgO
A16AX12trientine0.45 1)gO
B01AX07caplacizumab10mgP
B03AB10ferric maltol60mg Fe3+O
B06AC05lanadelumab21.4mgP
D01BA03fosravuconazole0.1 2)gO
H04AA01glucagon3mgN
H05BX05calcifediol30mcgO
J01DH52meropenem and vaborbactam3)gP
J01DH56imipenem, cilastatin and relebactam4)gP
J01MA25lascufloxacin75mgO
L04AC17tildrakizumab1.11mgP
L04AC18risankizumab1.67mgP
N03AX25cenobamate0.2gO
N05CD08midazolam5mgN
N05CD08midazolam10mgSL
N07BC01buprenorphine2.1mgP
1) expressed as trientine
2) expressed as ravuconazole
3) Refers to meropenem
4) Refers to imipenem

Last updated: 2022-12-19